Abstract Number: PB0725
Meeting: ISTH 2022 Congress
Background: Recently, Von Willebrand factor antigen (vWF-Ag) has been identified as a new marker of portal hypertension (PH) and its complications, but untill now, no published study discuss its predictive value for portal hypertensive gastropathy (PHG) . This marker is considered as a non-invasive approach, In order to avoid the endoscopic burden, cost, drawbacks, unpleasant and repeated examinations for patients.
Aims: To evaluate the ability of vWF-Ag in the prediction of PHG, which is diagnosed by endoscopic tools.
Methods: One hundred twenty-four patients with liver cirrhosis were included in this study. Patients with no history of bleeding who underwent screening endoscopy for PH related complications like: esophageal varices (EVs) and PHG. vWF-Ag testing was performed by immunoturbidimetric technique. The diagnostic performance of our marker was assessed using sensitivity, specificity, positive predictive value, negative predictive value, accuracy and receiver operating characteristic curves.
Results: Screening endoscopy revealed the presence of 20.2% PHG cases, and 83.1% EVs cases. vWF-Ag levels, were significantly increased in patients with PHG compared to those who have not: 441% [CI: 375 – 506], versus 279% [CI: 253 – 304], respectively (p < 0.0001). vWF-Ag was a good predictor for the presence of PHG. With a cut-off value of 320% and an AUC of 0.824, vWF-Ag had an 84% sensitivity, 74% specificity, 44.7% positive predictive value, 94.8% negative predictive value and 75.8% diagnostic accuracy.
Conclusion(s): vWF-Ag is a good non-invasive affordable marker for excluding the presence of PHG in patients with liver cirrhosis. Using this marker as part of a selective screening strategy, might reduce the coast of patient care and the need for endoscopic screening.
To cite this abstract in AMA style:El Horri M, El Horri F, Chikh Khelifa A, Chekkal M, Benbouhadi K, Mimene H, Kebir K, Benhalima K, Benglia A, Benmahdi L, BROUK H. Role of von Willebrand factor Antigen as Non-invasive Biomarker for the Prediction of Portal Hypertensive Gastropathy in Patients with Liver Cirrhosis [abstract]. https://abstracts.isth.org/abstract/role-of-von-willebrand-factor-antigen-as-non-invasive-biomarker-for-the-prediction-of-portal-hypertensive-gastropathy-in-patients-with-liver-cirrhosis/. Accessed December 6, 2023.
« Back to ISTH 2022 Congress
ISTH Congress Abstracts - https://abstracts.isth.org/abstract/role-of-von-willebrand-factor-antigen-as-non-invasive-biomarker-for-the-prediction-of-portal-hypertensive-gastropathy-in-patients-with-liver-cirrhosis/